Alzheimer's

Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

Fri, 24 Feb 2023 16:57:10 +0000

Summary

“Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies provides comprehensive information about the Alzheimer pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Alzheimer is a progressive neurologic disorder beginning with mild memory loss and possibly leading to loss of the ability to carry on a conversation and respond to the environment.

Scope

Extensive coverage of the Alzheimer under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Alzheimer and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoi...

$4,000.00

Dementia Associated With Alzheimers Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 15:59:09 +0000

Summary

Dementia Associated With Alzheimer's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built usin...

$2,000.00

Alzheimer's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 08 Apr 2022 11:35:28 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the ...

$2,500.00

Alzheimer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020

Tue, 12 Oct 2021 12:51:41 +0000

Alzheimer Diagnostic Tests are test that detects the disease before it causes the symptoms. It measures key proteins or protein patterns in blood or spinal fluid (biomarkers). GlobalData's Medical Devices sector report, “Alzheimer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Alzheimer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Alzheimer Diagnostic Tests Pipeline Assessment report provides key information and data related to: Extensive coverage of the Alzheimer Diagnostic Tests under development Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates Reviews of major players involved in the pipeline product development. Provides key clinical trial data related to ongoing clinical trials such as tria...

$4,000.00

Alzheimer's disease (AD)- Market Insight, Epidemiology and Market Forecast -2030

Mon, 15 Jun 2020 14:30:13 +0000

DelveInsight's "Alzheimer's disease (AD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Alzheimer's disease (AD), historical and forecasted epidemiology as well as the Alzheimer's disease (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Alzheimer's disease (AD) market report provides current treatment practices, emerging drugs, Alzheimer's disease (AD) market share of the individual therapies, current and forecasted Alzheimer's disease (AD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alzheimer's disease (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2017-2030 Alzheimer's disease (AD) Disease Und...

$6,950.00

Alzheimer's Disease: Epidemiology Forecast to 2028

Mon, 15 Jun 2020 14:30:13 +0000

Summary Alzheimer’s Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly. AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities including thinking, language, and learning capacity (National Institute on Aging, 2019). AD is the most common type of dementia (Centers for Disease Control and Prevention, 2019). The publisher epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for AD was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of AD in the 8MM, segmented by age, sex, and severity. The following data describes epidem...

$7,990.00

Alzheimer’s Disease: Global Drug Forecast and Market Analysis to 2028

Mon, 15 Jun 2020 14:30:13 +0000

Summary Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of the disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation, either by a home care professional or a family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL) for both patients and their caretakers. With rapidly increasing worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made to develop a new treatment for AD, as current pharmacologic management is known to only provide a temporary improvement in symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area of opportunity exists for the development of an effective pharmacologic approach. The current competitive landscape in AD consists only of s...

$21,990.00

Alzheimer Disease Drugs Markets in China

Wed, 09 May 2018 11:25:43 +0000

China's demand for Alzheimer Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews ar...

$4,000.00

Alzheimer Disease Drugs Industry Forecasts - China Focus

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Alzheimer Disease Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal in...

$1,800.00

Alzheimer Disease Drugs Companies in China

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Alzheimer Disease Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is su...

$1,800.00

Alzheimer's Disease Global Clinical Trials Review, H1, 2017

Fri, 12 May 2017 15:24:23 +0000

Summary

GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H1, 2017" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter str...

$2,500.00

Alzheimer's Disease - Heat Map and Analysis

Fri, 28 Apr 2017 10:35:57 +0000

Summary

Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. The pathological features of AD comprise a complex set of histopathological changes within the brain. Symptoms typically begin to first appear in patients in their mid-sixties, and appear in varying stages. The effects of AD, particularly at an advanced stage, are devastating to patients and their caregivers, and are associated with significant associated healthcare costs.

Current treatments focus on sustaining the patient’s cognitive function, managing behavioural symptoms and slowing down the rate of disease progression. There is currently no cure for AD, and only six symptomatic treatment therapies have been approved, of which one (Cognex) is no longer available in the US. The current market leaders are suboptimal in terms of efficacy, and there is therefore a large unmet need within AD to develop safer and more efficacious treatments.

There are numerous differences between many of ...

$2,000.00

Epiomic Epidemiology Series: Alzheimer's Disease Forecast in 12 Major Markets 2017-2027

Thu, 09 Mar 2017 15:20:59 +0000

Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is the leading cause of dementia. Alzheimer’s is associated with the increase of beta amyloid and tau proteins in the brains of affected patients. Cognitive function declines and patients suffer memory loss and disorientation amongst many other neuropsychiatric conditions as the disease progresses. This report provides the current prevalent population for Alzheimer’s disease across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Alzheimer’s have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are als...

$6,400.00

Alzheimer's Disease - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H2 2016’, provides an overview of the Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, co...

$2,500.00

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease (AD) for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Alzheimer’s disease (AD) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Alzheimer’s disease (AD) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Alzheimer’s disease (AD) market. • Identifying patient populations in the global “Alzheimer’s disease (AD) market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Alzheimer’s disease (AD) therapeutics in each of the markets covered...

$4,950.00

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

Wed, 01 Jun 2016 12:01:40 +0000

Summary

Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.

Scope
$4,995.00

Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

Wed, 01 Jun 2016 12:01:40 +0000

Summary

Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerably high at 559. The majority of the pipeline products are novel drugs, with a total of seven repositioned and five generic drugs. This shows advancement in the progression of the different molecules being developed as therapeutic agents within the AD pipelin...

$4,995.00

Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016

Tue, 31 May 2016 09:45:03 +0000

Summary

Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global ...

$2,000.00